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We have examined the in vitro induction and activity of feline immunodeficiency virus (FMV)-specific cytolytic
T cells obtained from cats experimentally infected for 7 to 17 weeks or 20 to 22 months with the Petaluma isolate
of FIV. Normal or FIV-infected autologous and allogeneic T lymphoblastoid cells were used as target cells in
chromium-51 or indium-ill release assays. When effector cells consisted of either fresh peripheral blood
mononuclear cells or concanavalin A- and interleukin-2-stimulated cells, only low levels of cytotoxicity were
observed. However, the levels of FIV-specific cytotoxicity were consistently higher in both groups of cats
following in vitro stimulation of the effector cells with irradiated, FIV-infected autologous T lymphoblastoid
cells and interleukin-2. The effector cells lysed autologous but not allogeneic FIV-infected target cells and were
composed predominantly of CD8+ T cells, indicating that the FIV-specific cytotoxicity measured in this system
is mediated by CD8+, major histocompatibility complex class I-restricted T cells. These studies show that
FIV-specific cytolytic T cells can be detected as early as 7 to 9 weeks postinfection, and they define a system to
identify virus-encoded epitopes important in the induction of protective immunity against lentiviruses.
Feline immunodeficiency virus (FIV) is currently consid-
ered a valuable small-animal model for human immunodefi-
ciency virus (HIV)-induced AIDS in humans (2, 4, 8, 11, 17,
24, 33, 39, 43, 53-55). The observation that humans may be
infected with HIV-1 for long periods without clinical illness
suggests that a natural immune mechanism must be capable
of inhibiting the spread of viral infection (49). Cell-mediated
immune mechanisms, especially HIV-1-specific cellular cy-
totoxicity, may be particularly important in host defense
against this virus by destroying virus-infected cells (12, 16,
25, 34, 35, 46) and suppressing viral replication (18, 44, 50).
Cytotoxic T lymphocytes (CTL) directed against HIV-1
have been detected in HIV-infected humans (9, 10, 14, 16,
20, 22, 23, 30, 35, 36, 38, 46-48), in human volunteers
vaccinated with soluble gpl60 (31), and in chimpanzees
immunized with recombinant vaccinia virus expressing
HIV-1 envelope glycoproteins (56). Simian immunodefi-
ciency virus (SIV)-specific CTL were also observed in
infected (26-28, 45, 52) and vaccinated (13, 37) primates.
Although most studies reported that the effector cells were
CD8+ major histocompatibility complex (MHC) class I-re-
stricted T cells, HIV-specific CD4+ MHC class II-restricted
CTL were observed in HIV-seronegative humans (40), vac-
cinated human volunteers (31), and chimpanzees (56). Sim-
ilarly, SIV gag-specific CD4+ MHC class II-restricted CTL
were detected in immunized macaques (29).
Compared with SIV and HIV infections, little is known
about cell-mediated immune responses in FIV-infected cats.
Research in our laboratory is directed toward elucidating the
FIV-specific cellular immune responses that participate in
the development of protective immunity or immunopathol-
ogy associated with lentiviral infection or vaccination. Here
we report, for the first time, the detection of MHC-re-
stricted, FIV-specific cytotoxic T lymphocyte responses in
cats experimentally infected with FIV.
* Corresponding author.
MATERIALS AND METHODS
Experimental animals. The 13 domestic, specific-patho-
gen-free (SPF) cats (Liberty Laboratories, Liberty Corner,
N.J.) selected for this study were serologically negative for
FIV, feline syncytium-forming virus, feline coronavirus, and
feline leukemia virus. Cats were housed under SPF condi-
tions at the Laboratory of Animal Research and Resources
Facilities, Texas A&M University, College Station. All
animals were maintained in accordance with the Guide for
the Care and the Use of Laboratory Animals, Department of
Health and Human Services.
Viruses. The Petaluma isolate of FIV used for in vitro
infection of target cells was obtained from the National
Institute of Allergy and Infectious Diseases AIDS Research
and Reference Reagent Program (catalog no. 236) and was
prepared for use as a virus stock as described by Brown et
al. (5). Heparinized FIV-infected donor blood used to inoc-
ulate the SPF cats was collected from a cat with experimen-
tally induced FIV Petaluma infection and was kindly pro-
vided by Niels C. Pedersen, University of California, Davis.
Experimental infection. Two separate groups of cats were
inoculated intraperitoneally with heparinized FIV-infected
blood. In the first group (acutely infected), cats QB2, QB3,
and QB5 were inoculated intraperitoneally at 6 months of
age with 1.0 ml of FIV-infected blood and were monitored
from 1 to 17 weeks postinfection. Cats QA2 and QB4 served
as uninfected controls for this group. Virus-specific cellular
immune responses were examined weekly for the first month
and biweekly for the second month after FIV inoculation. In
the second group (chronically infected), cats EK3, ET4, and
EZ3 were inoculated at 1 year of age with FIV (57) and were
monitored from 59 to 89 weeks postinfection. Cats EC4,
ED3, EK6, ET5, and EY5 served as uninfected controls for
this group.
Serologic determinations. Serum antibody to FIV was
monitored by enzyme-linked immunosorbent assay
(IDEXX, Portland, Maine) and by Western immunoblot
analyses with virus from infected Crandell feline kidney
cells, goat anti-cat immunoglobulin G conjugated with alka-
line phosphatase as the secondary antibody, and 5-bromo-4
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chloro-3-indolylphosphate toluidinium-Nitro Blue Totra-
zolium (BCIP-NBT) substrate (Kirkegaard & Perry Labora-
tories, Inc., Gaithersburg, Md.).
Flow cytometry. The percentages of CD4+ and CD8+ T
cells in peripheral blood mononuclear cell (PBMC) or in
lymphoblastoid cell lines were determined as described
previously (5) by indirect immunofluorescence staining and
flow cytometry with mouse monoclonal antibodies (kindly
provided by Chris Ackley and Max Cooper, University of
Alabama, Birmingham) specific for feline CD4 (1) and CD8
(19) determinants.
PCR analysis. PBMC were obtained from heparinized
blood of control and FIV-infected cats by Ficoll-sodium
diatrizoate (Histopaque-1077; Sigma Chemical Co., St.
Louis, Mo.) density gradient centrifugation. Genomic DNA
was extracted from the cells by the technique of Weintrub et
al. (51). An aliquot of 5 x 105 cells was washed in phosphate-
buffered saline and pelleted at 250 x g for 5 min. The
resulting pellet was resuspended in 25 ,ul of solution A (100
mM KCl, 10 mM Tris [pH 8.3], 2 mM MgCl2)-25 pAl of
solution B (10 mM Tris [pH 8.3], 2 mM MgCl2, 1% Tween
20, 1% Nonidet P-40, 120 ,ug of proteinase K per ml). The
cell lysate was incubated at 60°C for 1 h and then subjected
to heat inactivation of proteinase K in a boiling-water bath
for 10 min. No further purification of the sample was
necessary. Polymerase chain reaction (PCR) primers (up-
stream [5'-TACATCTGGTGACTCTTCGC-3'] and down-
stream [5'-CT'lTCCTCCTCCTACTCCAA-3']) for the gag
gene were chosen from the published sequence of the FIV
genome (42) by using the OligoTM software (MBI, Ply-
mouth, Minn.) and were synthesized by Biosynthesis, Den-
ton, Tex. The PCRs were carried out with 100-pI reaction
volumes (0.25 mM nucleotide mix, 5 U of Taq DNA poly-
merase [Promega, Madison, Wis.], 0.15 puM upstream
primer, 0.15 puM downstream primer, PCR reaction buffer
containing 1.5 mM MgCl2 [Promega]) for 30 or 40 cycles,
with a denaturation temperature of 94°C for 1 min, an
annealing temperature of 52°C for 30 s, and an extension
temperature of 72°C for 1 min. Ten percent of the resulting
PCR sample was run on a 1% agarose gel at 60 V for 2 h
and transferred by Southern blotting to nylon membranes
(GeneScreen Plus; Dupont NEN, Boston, Mass.). The
cloned gag long terminal repeat DNA (kindly provided by
John Elder, Scripps Research Institute, La Jolla, Calif.) was
labeled by the random-primer method with [32P]dCTP
(Boehringer Mannheim Biochemicals, Indianapolis, Ind.).
The membrane was hybridized overnight with thegag probe
(2 x 109 cpm) by using the rapid-hybridization solution from
Amersham, Arlington Heights, Ill., as specified by the
manufacturer. The blot was washed twice in 2x SSPE (lx
SSPE is 0.18 M NaCl, 10 mM NaPO4, and 1 mM EDTA [pH
7.7])-0.1% sodium dodecyl sulfate (SDS) for 10 min at room
temperature, once in ix SSPE-0.1% SDS for 15 min at 65°C,
twice in 0.5x SSPE-0.1% SDS for 10 min at 65°C, once in
0.2x SSPE-0.1% SDS for 30 min at 65°C, and once in O.lx
SSPE-0.1% SDS for 30 min at 65°C. The membrane was
exposed to autoradiography film (Amersham Hyperfilm MP)
at room temperature overnight.
Preparation of target cells for cytotoxicity assays. Heparin-
ized blood was drawn from the cats before FIV infection.
PBMC were isolated by Ficoll-sodium diatrizoate density
gradient centrifugation and were used to prepare T lympho-
blastoid cells. The PBMC were stimulated with 5 pug of
concanavalin A (ConA) (Sigma Chemical Co.) per ml of
complete RPMI 1640 medium (5) for 3 days at 37°C in a
humidified atmosphere of 5% CO2 in air. The cells were
cultured at a concentration of 1.5 x 106 to 3 x 106/ml of
complete medium in a 24-well plate (Costar, Cambridge,
Mass.). The ConA-stimulated PBMC were then resuspended
in complete medium supplemented with 10% bovine T-cell
growth factor (TCGF), prepared as described previously (6),
and 20 U of human recombinant interleukin-2 (IL-2; Boehr-
inger Mannheim Biochemicals) per ml and were cultured for
an additional 1 to 2 weeks (5). The cells were aliquoted and
stored in liquid nitrogen for later use as normal autologous
target cells. The lymphoblastoid cells were infected in vitro
with FIV Petaluma as described previously (5). A stock of
virus grown in feline T cells with a reverse transcriptase (RT)
activity of 1.24 x 106 cpm/ml was used for in vitro infection.
Uninfected and infected cells were maintained in 24-well
plates at a density of 3.3 x 105 cells per ml of complete
medium supplemented with TCGF and IL-2. Cell viabilities
were monitored by trypan blue dye exclusion. When the
percentage of viable cells decreased to 70% or less, an equal
number of uninfected autologous lymphoblasts were added
to the cultures. The viral infectivity of cultured cells was
determined by measuring RT activity in culture supernatants
(5) and by the indirect immunofluorescent-antibody test
(IFAT) with normal, feline syncytium-forming virus-spe-
cific, and FIV-specific feline sera as described previously
(5). The FIV-infected cells were aliquoted and stored in
liquid nitrogen for use as autologous or allogeneic target cells
and as stimulator cells for the establishment of FIV-specific
T-cell lines.
Cytotoxic effector cells. Three kinds of effector cells were
used in this study: fresh PBMC, ConA- and IL-2-stimulated
PBMC, and FIV-stimulated T-cell lines. PBMC were ob-
tained from control cats or from infected cats at various
times following experimental FIV infection. To prepare
ConA blasts, PBMC were stimulated with 5 jig of ConA per
ml for 3 days and then with 10% bovine TCGF and 20 U of
IL-2 per ml for an additional 4 to 5 days. FIV-specific T-cell
lines were established by repeated stimulation of T cells with
FIV. Briefly, 2 x 106 to 3 x 106 PBMC were cultured for 1
week with 1.5 x 105 to 2 x 105 irradiated (10,000 rads from
a 60Co source) autologous FIV-infected lymphoblastoid cells
in complete medium in 1.5-ml cultures in 24-well plates.
Viable responder cells were purified by Ficoll-sodium diatr-
izoate density gradient centrifugation, and 106 cells were
restimulated at weekly intervals with irradiated, autologous
FIV-infected PBMC plus 20 U of IL-2 per ml of complete
medium. The cells were subcultured 3 to 4 days after
antigenic stimulation. At 4 to 7 days after antigenic stimula-
tion, viable cells were purified by Ficoll-sodium diatrizoate
density gradient centrifugation and used as effector cells in
the cytotoxicity assay. Cells cultured with irradiated, autol-
ogous FIV-infected cells for 1.5 to 4 weeks were assayed.
When enough cells were available at the time of the cyto-
toxicity assay, the percentages of CD4+ and CD8+ T cells in
the effector cell population were determined by indirect
immunofluorescence and flow cytometry (5).
Cytotoxicity assay. Chromium-51 (3, 46) and indium-111 (7)
release assays were compared for efficiency of labeling feline
target cells. For the 51Cr release assay, 106 target cells were
pelleted by centrifugation and labeled with 50 ,iCi of Na51
CrO4 (NEZ-030S; Du Pont NEN) for 1 to 3 h at 370C with
gentle agitation at 30-min intervals and then washed three
times with complete medium. For the indium-111 release
assay, 106 target cells were labeled with 5 ,uCi of indium-111
oxine (Medi-Physics, Inc., Arlington Heights, Ill.) for 15 min
at 37°C and then washed five times with complete medium. A
fixed number of 5'Cr-labeled (5 x 104) or "'In-labeled (5 x
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FIG. 1. CD4+/CD8+ T-cell ratio in PBMC from FIV-infected cats. (A) Cats acutely infected with FIV (group 1); (B) control SPF cats for
group 1; (C) cats chronically infected with FIV (group 2); (D) control SPF cats for group 2.
103) target cells was added to each well of 96-well V-bot-
tomed plates (Costar). Effector cells were added in triplicate
at various effector/target (E/T) cell ratios in a total volume of
200 Rl per well. When fresh PBMC and ConA blasts were
used as effector cells, EST ratios of 100:1, 50:1, 25:1, and
12.5:1 were used. When FIV-specific T-cell lines were used
as effector cells, E/T ratios of 20:1, 10:1, 5:1, and 2.5:1 were
used. The plates were centrifuged at 250 x g for 1 to 2 min,
incubated at 37°C for 4 h, and then centrifuged again at 250
x g for 5 min. Supernatants (100 RI) were collected from
each sample and counted in a gamma counter. The maximum
isotope release was determined by using triplicate samples of
radiolabeled target cells subjected to three cycles of freezing
and thawing, followed by centrifugation at 5,000 x g for 5
min. Spontaneous release of the isotope was determined by
using supernatants of radiolabeled target cells incubated in
the assay plate in the absence of effector cells. Spontaneous
isotope release was less than 15% of the maximum isotope
release for all target cells used in the assay. The percentage
of specific cytotoxicity or isotope release was calculated as
100 x (mean cpm test release - mean cpm spontaneous
release)/(mean cpm maximum release - mean cpm sponta-
neous release) for triplicate samples.
RESULTS
Experimental infection of cats with FIV. The presence of
FIV-specific antibody in infected cats was determined
weekly following FIV inoculation of acutely infected cats
QB2, QB3, and QB5. The cats seroconverted by 5, 7, and 4
weeks postinfection, respectively. The ratios of CD4+ to
CD8+ T cells in PBMC declined in two of the cats, QB2 and
QB5, dropping to < 1.0 by 20 weeks postinfection (Fig. 1A).
In contrast, during the same period, the ratio of CD4+ to
CD8+ T cells remained > 1 in FIV-infected cat QB3 (Fig. 1A)
and in control cats QA2 and QB4 (Fig. 1B). Cats EK3, ET4,
and EZ3, which were chronically infected with FIV, sero-
converted by 8 weeks postinfection (57). The ratios of CD4+
to CD8+ T cells in the PBMC of these cats dropped to 1 or
< 1 by 25 weeks postinfection and remained low (through 86
weeks postinfection) (Fig. 1C). In contrast, control cats for
the chronically infected group did not experience a compa-
rable decline in the CD4+ to CD8+ T-cell ratios (Fig. 1D).
Serum samples from all FIV-infected cats reacted with FIV
on Western blots (data not shown). The presence of virus in
both acutely and chronically infected cats was confirmed by
PCR analysis of PBMC obtained at the time of this study
(Fig. 2). gag sequences, which were absent from PBMC of
all control cats (lanes 3, 6, 8, and 10) could be demonstrated
in PBMC of all acutely (lanes 2, 5, and 7) and chronically
(lanes 9, 11, and 13) infected cats.
In vitro infection of ConA blasts with FIV. ConA- and
IL-2-stimulated lymphoblastoid cell lines were established
from cats QB2, QB3, QB5, and EK3 before the cats were
experimentally infected with FIV. The cells were maintained
in culture for 1 to 3 weeks and were then infected with FIV
Petaluma. Uninfected cell lines could be maintained for up to
7 weeks with cell viabilities of 85 to 95%. However, by 6 to
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FIG. 2. Detection of FIVgag sequences in PBMC of experimen-
tally FIV-infected cats by PCR. PBMC from acutely infected cats
QB2, QB3, and QB5 are shown in lanes 2, 5, and 7, respectively.
PBMC from chronically infected cats EK3, ET4, and EZ3 are shown
in lanes 9, 11, and 13, respectively. PBMC from uninfected cats
QA2, QB4, EC4, and EK6 are shown in lanes 3, 6, 8, and 10,
respectively. Molecular size markers are shown in lane 1. All lanes
represent PCR assays of 40 cycles, except the assays with PBMC
from cats QB3, EK3, and ET4, for which 30 cycles were used.
8 days after in vitro infection with FIV, cell viabilities
dropped to 60 to 75%, and addition of autologous, uninfected
lymphoblastoid cells was required to maintain the cell lines.
Cells were examined by IFAT for the presence of viral
antigen, and by 6 to 8 days after in vitro infection, 60 to 80%
of the cells expressed FIV (Fig. 3C). Normal lymphoblastoid
cells were negative by IFAT for FIV (Fig. 3A), and FIV-
infected cells did not stain with normal feline serum (Fig. 3B)
or with an antiserum directed against feline syncytium-
forming virus (Fig. 3D). Viral replication was confirmed by
measuring RT activity in the culture supernatants of FIV-
infected cells collected over a 3-week period (Fig. 4). Peak
levels of RT were observed in supernatants on day 8
postinfection, coincident with the high percentage of FIV+
cells visualized by IFAT. Cell surface phenotypic analyses
of FIV-infected cells showed that most of the cells expressed
CD4 (data not shown).
Uninfected and FIV-infected T-cell lines were similarly
established from PBMC of chronically infected cats ET4 and
EZ3 approximately 1 year after infection. Although cell lines
were established from these two cats, which had a latent FIV
infection, none of the uninfected cell lines expressed viral
antigen during the culture period as determined by IFAT
(data not shown).
Target cell labeling. 51Cr and "11In were compared for their
efficiency of labeling of both uninfected and FIV-infected
feline T cells (Table 1). Maximum labeling of target cells with
51Cr occurred when cells were incubated with the isotope for
3 h. Because the spontaneous release of the isotope was 15%
or less, these conditions were used in 51Cr release assays.
However, equally efficient incorporation of radioactivity
was achieved with 10-fold fewer target cells labeled with
FIG. 3. Immunofluorescence staining of FIV proteins expressed in feline lymphoblastoid cells obtained from cat QB2 8 days after in vitro
infection. Uninfected cells (A) and FIV-infected cells (B to D) were stained with normal feline serum (panel B), FIV-specific feline serum
(panels A and C), or feline syncytium-forming virus-specific feline serum (panel D).
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FIG. 4. RT activities in culture supernatants harvested on the
indicated days after in vitro infection of feline lymphoblastoid cells
obtained from cat QB2. The arrow indicates that autologous unin-
fected cells were added to the culture 8 days after infection and on
alternate days thereafter.
"1In for 15 min, with comparable levels of spontaneous
isotope release. Because cytotoxicity assays with llIn-
labeled target cells required 10-fold fewer target cells and
effector cells, this isotope was selected for use in most of the
experiments.
Detection of FIV-specific cytotoxic responses in FIV-infected
cats. FIV-specific cytotoxic T-cell activity was examined in
fresh PBMC, ConA blasts, and T-cell lines stimulated for 1.5
to 4 weeks with autologous, irradiated FIV-infected lympho-
cytes. No cytotoxicity of any target cell was detected with
PBMC obtained from any of the acutely infected cats QB2
(Table 2), QB3 (Table 2; Fig. 5A), or QB5 before or up to 4
weeks following FIV infection. At 7 weeks postinfection,
FIV-specific cytotoxicity ranging from 3 to 7% (with an E/T
ratio of 100:1) was observed with ConA- and IL-2-stimulated
lymphoblasts obtained from all three FIV-infected cats. An
example of cytotoxicity mediated by lymphoblasts obtained
from cat QB3 is shown in Fig. SB. FIV-specific T-cell lines
established from PBMC obtained 9 weeks postinfection
exhibited specific killing of autologous FIV-infected target
cells of 7.7% (QB2), 15.8% (QB3; Fig. SC), and 28.9% (QB5)
at an E/T ratio of 20:1. Similar levels of FIV-specific
cytotoxicity from these three cats were again observed in
cell lines established 17 weeks postinfection (Fig. SD; Table
TABLE 1. Comparison of the efficiency of radiolabeling feline
T-cell blasts with 51Cr and "'In
Maximum release of radioactivity
Isotope and incorporated by feline T cellsb
labeling perioda
Uninfected FIV infected
5"Cr
1.0 h 5,240 + 128 (3.8) 2,214 + 85 (5.8)
1.5 h 6,164 + 272 (4.3) 3,601 105 (6.4)
3.0 h 15,439 340 (5.2) 7,969 279 (9.2)
"l'In
15 min 10,688 + 260 (2.3) 12,669 + 157 (10.6)
a Cells were labeled with either "Cr (5 x 104 cells per well) or "'In (5 x 103
cells per well) for the times indicated.
b Data are shown as the mean cpm + standard deviation of triplicate
samples. Numbers in parentheses indicate the spontaneous release calculated
as a percentage of the maximum release.
TABLE 2. Cytotoxicity responses and phenotypic analyses of
feline T cells stimulated in vitro with FIV-infected cells
Cat Days in % Specific CD8/CD4 ratio
culture cytotoxicitya of effector cells'
Normal
QA2 12 0.6 1.8
QB4 12 0.4 1.8
FIV infected
QB2 0C 0 0.4
16 6.4 3.9
QB3 0C 0 0.5
16 17.5 10.8
EK3 0C 1.6 0.8
24 30.5 10.0
ET4 0O 0 0.9
14d 11.7 4.7
lgd 8.7 32.7
EZ3 0C 0 1.0
19 14.6 3.6
a Data obtained by using EST ratios of 100:1 for PBMC and 20:1 for
FIV-stimulated T-cell lines in a 4-h "1'In release assay.
bThe ratios of CD8+ to CD4+ T cells in the effector cell populations were
determined at the time of assay.
c Freshly isolated PBMC.
d Data from two separate T-cell lines are presented.
2). No killing of uninfected autologous or FIV-infected
mismatched target cells occurred.
At 22 weeks postinfection, PBMC from control cats QA2
and QB4 were stimulated for 12 days with autologous,
FIV-infected lymphocytes and were tested for cytotoxicity.
There was no detectable killing of uninfected autologous
target cells, FIV-infected autologous target cells, or FIV-
infected allogeneic target cells (Table 2).
PBMC from the chronically infected cats were then exam-
ined for FIV-specific cytotoxicity. PBMC obtained 59 weeks
postinfection from cat EK3 exhibited low levels of killing
against FIV-infected autologous target cells, reaching a
maximum of about 10% with an E/T ratio of 50:1 (Fig. 6A).
ConA- and IL-2-stimulated lymphoblasts derived from EK3
PBMC obtained at 61 weeks postinfection exhibited a similar
level of killing at all E/T ratios tested (Fig. 6B). On other
occasions, no cytotoxicity could be detected with either
PBMC or lymphoblasts from this cat (data not shown).
FIV-specific T-cell lines established from this cat 62 to 72
weeks postinfection showed a higher specific lysis of FIV-
infected autologous target cells. For example, cytotoxicity
ranging from 19.0 to 30.5% with an E/T ratio of 20:1 in a cell
line stimulated for 10 or 24 days is shown in Fig. 6C and D,
respectively. No killing of FIV-infected allogeneic target
cells was seen, but low levels of killing of uninfected
autologous target cells occasionally occurred (Fig. 6C).
No cytotoxicity was observed with either PBMC or ConA
blasts from infected cats ET4 and EZ3 when tested 82 to 89
weeks postinfection (data not shown). However, FIV-spe-
cific T-cell lines established from PBMC of these two cats at
82 to 84 weeks postinfection exhibited 11.7 and 14.6%
specific killing of autologous FIV-infected target cells, with
an E/T ratio of 20:1 (Table 2). Background levels of cytotox-
icity against uninfected autologous cells or FIV-infected
allogenic targets were less than 4%.
Cell surface phenotype analysis of the effector CTL popu-
lation. Stimulation of PBMC from infected cats with FIV-
infected T cells and IL-2 appeared to selectively induce the
proliferation of CD8+ T cells, since cells cultured with
antigen for 14 to 24 days contained a higher proportion of
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FIG. 5. FIV-specific cytotoxicity in acutely infected cat QB3. PBMC obtained before infection (A), lymphoblastoid cells obtained 7 weeks
postinfection (PI) (B), an FIV-specific T-cell line established from PBMC obtained 9 weeks postinfection and cultured for 21 days with
irradiated autologous FIV-infected T cells (C), and an FIV-specific T-cell line established from PBMC obtained 17 weeks postinfection and
cultured for 16 days with irradiated autologous FIV-infected T cells (D) were used as effector cells. Normal autologous cells (0), FIV-infected
autologous cells (@), and FIV-infected allogeneic cells (A) were used as target cells.
CD8+ T cells than unstimulated PBMC did (Table 2). Fur-
thermore, the degree of FIV-specific cytotoxicity tended to
correlate with the proportion of CD8+ T cells in the effector
cell population. Low levels of killing of normal autologous
target cells were occasionally observed (Fig. 6), whereas
similar levels of cytotoxicity directed against allogeneic
FIV-infected target cells were never detected (Fig. 5 and 6).
Although the MHC class I phenotypes for these cats have
not been determined, our results are consistent with the
hypothesis that lysis of FIV-infected target cells is mediated
in part by MHC class I-restricted, CD8+ CTL.
DISCUSSION
The results of this study demonstrate the presence of
FIV-specific, MHC-restricted CTL precursor cells in the
peripheral blood of cats experimentally infected with FIV.
Two groups of cats were included in the study: acutely
infected (for less than 5 months) and chronically infected (for
1 to 1.5 years) cats. For the duration of this study, FIV-
infected cats remained clinically healthy, although a de-
crease in the ratio of CD4+ to CD8+ T cells in PBMC by 20
to 25 weeks postinfection in five of the six cats and the early
appearance of a humoral immune response in all animals
were observed as previously reported for FIV-infected cats
(2, 4, 39, 43). Furthermore, at the time of this study, the FIV
genome was detected by PCR analysis in PBMC of all
acutely and chronically infected cats. As with humans in-
fected with HIV, cats infected with FIV may remain clini-
cally healthy for years, suggesting that FIV-specific host
immunity may play a role in preventing the development of
AIDS-like disease in these animals.
To examine the potential role of FIV-specific cytotoxic T
cells in the protective immune response against FIV in
infected cats, we adopted a modified cytotoxicity protocol in
which "'In was used to radiolabel lymphoblastoid target
cells (7). The use of this isotope enabled the detection of
cytotoxicity with 10-fold fewer target and effector cells, an
important consideration when working with an outbred
population of small animals. FIV-specific cytotoxicity was
first detected in ConA- and IL-2-activated T cells from all
three acutely infected cats 7 weeks after infection, but
detection of CTL activity in either PBMC or lymphoblasts in
the chronically infected cats was inconsistent. However,
FIV-specific cytotoxic responses in all cats were consider-
ably augmented following in vitro antigenic stimulation of T
cells. This finding is explained most easily by a clonal
expansion and differentiation of CTL precursor populations
in PBMC into mature CTL, as has been demonstrated with
lymphocytes from HIV-seropositive humans and SIV-in-
fected primates (9, 10, 16, 21, 23, 38).
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FIG. 6. FIV-specific cytotoxicity in chronically infected cat EK3. PBMC obtained 59 weeks postinfection (A), lymphoblastoid cells
obtained 61 weeks postinfection (B), and an FIV-specific T-cell line established from PBMC obtained 72 weeks postinfection and stimulated
in vitro with FIV-infected autologous T cells for 10 (C) or 24 (D) days were used as effector cells. Symbols are the same as those defined for
Fig. 5.
The intensities of FIV-specific cytotoxic responses by
PBMC with or without a brief stimulation with the T-cell
mitogen ConA and IL-2 were lower than those reported for
PBMC or ConA blasts of HIV-seropositive humans (14, 19,
22, 30, 46, 48) or SIV-infected primates (26-28). In addition,
we were unable to detect cytotoxic T-cell responses in
lymphoblasts sampled before 7 weeks postinfection,
whereas SIV-specific cytotoxicity mediated by PBMC was
detected as early as 2 weeks after infection of macaques (26).
Several studies have reported the induction of HIV enve-
lope-specific CTL from PBMC of seronegative individuals
following a brief coculture with autologous HIV-infected
lymphoblasts (9, 16, 23) or after stimulation with gpl20-
pulsed monocytes (40), indicating the existence of HIV
envelope-reactive precursor cells in uninfected individuals.
In contrast, we were unable to induce FIV-specific CTL by
in vitro stimulation of PBMC from two uninfected cats with
autologous FIV-infected T cells. Therefore the higher levels
of lentivirus-specific CTL activity in humans and simians
than in cats may be due to a higher frequency of lentivirus-
reactive CTL precursors in humans and nonhuman primates.
Alternatively, the FIV-specific CTL may be directed against
antigens other than envelope proteins, since gag-specific
CTL precursor populations have not been detected in HIV-
seronegative individuals (9, 21, 22).
Another explanation for the comparatively low levels of
specific cytotoxicity observed in our studies may be the use
of FIV-infected, IL-2-activated T-cell blasts as target cells.
To maintain the cells in a viable state, we added an equiva-
lent number of uninfected autologous lymphoblasts to the
infected-cell cultures at frequent intervals so that the per-
centage of infected cells in the target cell population at any
given time was in the range of 60 to 80%. Despite this
limitation, infected T cells are the natural target cells in an
infected animal, and therefore the cytotoxicity measured in
vitro was probably directed against viral antigens which
would be encountered during a natural infection in vivo. The
target cells consisted of a mixture of CD4+ and CD8+ T
cells, and although we have shown that both T-cell subsets
can be infected by FIV in vitro (5), we have not yet
determined the relative susceptibilities of the two cell types
to CTL-mediated killing.
The frequency and activity of HIV- and SIV-specific CTL
appear to decline with the progression of disease (15, 16, 27,
32, 45, 46). By using FIV-stimulated T-cell lines, we found
that FIV-specific killing was mediated by lymphocytes sam-
pled from all three acutely infected cats at 9 and 17 weeks
postinfection and that even higher levels of cytotoxicity
were effected by T cells obtained from all three chronically
infected cats approximately 1.5 years postinfection. This
finding is probably explained by the clinically healthy status
of the chronically infected cats. Even though the CD4+/
CD8+ T-cell ratios in PBMC had dropped significantly, the
ratios were still approximately 1.0. The demonstration of
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CTL precursors in clinically healthy FIV-infected cats up to
1.5 years after the initial exposure to the virus supports the
current hypothesis that cytotoxic T lymphocytes may play
an important role in host defense against lentiviral infections
(12, 16, 25, 34, 41, 46).
Cell surface phenotypic analysis of several of the CTL
lines analyzed in this study indicated that most effector cells
in the population expressed CD8 and are therefore likely to
be MHC class I restricted. This is not surprising since
autologous FIV-infected T cells were used as antigen for
stimulating the cell lines in the absence of exogenous anti-
gen-presenting cells. Although we have no information re-
garding the MHC class I or class II phenotypes of our target
cells, virus-specific killing was apparently MHC restricted,
since allogeneic infected T cells were never lysed by CTL.
For this reason, cytotoxicity mediated by feline lymphocytes
was not due to natural killer-like killing, although we cannot
rule out the possibility that CD4+ MHC class II-restricted T
cells also contribute to cytotoxicity. The use of cloned T-cell
lines would more precisely define the effector cells mediating
FIV-specific killing of infected target cells.
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